ACVR1 and fibrodysplasia ossificans progressiva: Activating mutations in ALK2 increase SMAD phosphorylation and can lead to fibrodysplasia ossificans progressiva, a rare disabling disease characterized by heterotopic ossification (Fukuda et al. 2009; Kaplan et al. 2009).